Ryan began his career as a private equity investor at Celerity Partners, a $200 million private equity firm. During his time at Celerity, Ryan focused on technology related de-leveraging, growth equity, and leveraged recapitalization investments. Ryan led and participated in a broad range of new and portfolio company activity. Following Celerity, Ryan worked for Endeavour Capital, a $3 billion private equity firm focused on leveraged buyouts in the Northwestern United States. Finally, Ryan worked in the Palo Alto office of Summit Partners, a $35 billion global private equity group, where he focused on consumer internet, media, enterprise software, and semiconductor related investments.

In 2008, Ryan Jacob became Chairman and CEO of CAE. Ryan led the development of CAE into a global software and data driven trading platform for the semiconductor market that operates in 10 countries, has over 6,000 clients, over 300 employees, and is the market and technology leader in its space. Ryan became the largest CAE unitholder in a management buyout in 2014.

Ryan serves as Chairman of Jacob Family Holdings, LLC, a private investment company that focuses on investing in private equity and venture capital funds as a Limited Partner, acquiring and managing select private companies, and completing real estate investments in Texas, Utah, and California.

In addition to his leadership role at CAE, Ryan serves on the Board of Texas Semiconductor Technologies, a leading provider of aftermarket parts, systems, and solutions to the semiconductor industry. Ryan serves on the Board of the Prime Bank of Texas, an Austin-based community bank that serves select Texas markets. Ryan is the Chairman of TransformaTx Biotherapeutics, a biotechnology company focused on developing novel therapeutics for Angelman syndrome. Ryan serves on the Board of Sourceability, a global distributor of semiconductor and electronic components. Ryan has served on numerous boards in the past, including as the foundation representative for FAST (see below) on the board of GeneTx Biotherapeutics before and through the completion of its sale to Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE).

Ryan’s philanthropic efforts focus on adults and children with rare genetic diseases and intellectual and development disabilities. Ryan Jacob is the Executive Director, on the Board of Directors, of the Foundation for Angelman Syndrome Therapeutics (FAST), a research-focused foundation, dedicated to curing Angelman syndrome by funding foundational research in academic centers globally and transferring promising technology into therapy-specific companies. Ryan has served on the Board, and as Vice President of the Board, for the Arc of the Capital Area in the past, helping to establish a distributed network of care delivery centers in Central Texas.

Ryan holds a BA from the University of California, Los Angeles (UCLA).

Ryan lives in Austin, Texas with his wife and three children. Ryan’s middle son, Grayson, was diagnosed with Angelman syndrome.